Join to access to all OVN content. Join for Free
Prepare to LAUNCH: How to Build an MSL Team From Scratch
MSL team building drug launch strategy medical science liaison recruitment field medical team best practices MSL training phases

Prepare to LAUNCH: How to Build an MSL Team From Scratch


Share This Article


Summary

In episode 152, Tom Caravela is joined by John Caskey to delve into the intricacies of assembling the ideal MSL team for a successful drug launch. The discussion covers strategic timing, the importance of leadership, and the sequence of hiring MSLs. Operational requirements such as team size, territory allocation, and KOL support management are explored, alongside the recruiting timeline. The episode highlights key skills and criteria essential for selecting MSLs and emphasizes the need for comprehensive training, detailing how to balance different training phases. The conversation wraps up with a summary of best practices for building an effective field medical team.

Tom Caravela, Managing Partner at The Carolan Group and Host of the MSL Talk Podcast, is interviewed by Jon Kaskey on how to build an MSL team in preparation for a drug launch.
Tom shares….

👉 How early should companies consider hiring MSLs
👉 Who spearheads the process for building out the team
👉 What factors go into determining the number of MSLs per team
👉 How are territories aligned and allocated
👉 What other factors need to be considered for internal medical affairs preparedness

Click for Source
MSL team building, drug launch strategy, medical science liaison recruitment, field medical team best practices, MSL training phases

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Article
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
OVN Avatar Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy

Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review

Article
Clinical Educator Oncology Program Improves Adherence by 29%​
Partner Avatar iNIZIO

Clinical Educator Oncology Program Improves Adherence by 29%​

Article
New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures
OVN Avatar Forbes Books Press Release Official

New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures

Article
CheckMate-067: Raising the Bar for the Next Decade in Oncology
OVN Avatar Sarah A. Weiss, MD, and Harriet Kluger, MD

CheckMate-067: Raising the Bar for the Next Decade in Oncology

Explore OVN